Assessing platelet function may reduce platelet transfusion requirements in women in thrombocytopenia undergoing cesarean section

Specifically, the hemorrhagic adverse events in Group 2 referred to one of the following: (a) postartum hemorrhage (PPH) with blood loss of ≥1000 mL during cesarean; (b) diagnosis of anemia at discharge; and (c) required transfusion of blood components, such as red blood cells, plasma, and cryoprecipitate due to extensive drainage after the cesarean from the beginning of surgery until 72 hours postpartum. Items Group 1 (n = 147) Group 2 (n = 52) Group 3 (n = 85) Baseline characteristics Age (years) 28.45 ± 3.24 31.43 ± 3.99 30.63 ± 4.02 Gestational age (weeks) 34.94 ± 3.24∗ 33.89 ± 3.61∗ 36.16 ± 3.29 Twin pregnancy (yes/no) 8/139 2/50 1/84 Cause of thrombocytopenia (n) GP 46† 19† 62 ITP 1 0 2 Severe preeclampsia‡ 98† 31† 20 Rheumatism 1 2 1 Hematologic disease 1 0 0 Risk factors for hemorrhage (n) Uterine rupture 0 1 3 Placenta previa 0 1 4 Pernicious placenta previa 0 0 0 Placenta accreta 0 0 0 Placental abruption 12† 7† 0 Cesarean-scar pregnancy 31 8 18 Intrauterine fetal death 7 4 1 Liver disease 17∗ 10† 3 Anemia 0†,§ 22 23 Prepartum laboratory tests Fibrinogen (g/L) 3.95 ± 0.91 3.38 ± 1.21∗,† 4.01 ± 0.71 Hb on admission (g/L) 118.01 ± 17.44 109.41 ± 16.98 109.29 ± 22.97 Hb at discharge (g/L) 99.66 ± 16.70 91.34 ± 16.18‡ 95.05 ± 15.85 PLTs on admission (100 × 109/L) 58.37 ± 14.99† 50.15 ± 19.99‡ 47.63 ± 17.71 MA on admission (mm) 56.93 ± 7.50† 49.40 ± 11.61§ 52.50 ± 7.70 Hemorrhage volume and transfusion requirement Hemorrhage volume (mL) 211.05 ± 84.46 307.23 ± 328.27‡ 229.29 ± 117.89 Red blood cell (U) transfused (n) 0 0.80 ± 1.53∗,‡ 0.39 ± 1.27 Plasma (U) 0 0.83 ± 2.94∗,‡ 0.14 ± 0.90 Data are presented as n or mean ± standard deviation (range).∗ P